BR112014026138A2 - métodos de monitoramento terapêutico de pró-fármacos de ácido fenilacético - Google Patents

métodos de monitoramento terapêutico de pró-fármacos de ácido fenilacético

Info

Publication number
BR112014026138A2
BR112014026138A2 BR112014026138A BR112014026138A BR112014026138A2 BR 112014026138 A2 BR112014026138 A2 BR 112014026138A2 BR 112014026138 A BR112014026138 A BR 112014026138A BR 112014026138 A BR112014026138 A BR 112014026138A BR 112014026138 A2 BR112014026138 A2 BR 112014026138A2
Authority
BR
Brazil
Prior art keywords
phenylacetic acid
therapeutic monitoring
monitoring methods
acid prodrugs
paa
Prior art date
Application number
BR112014026138A
Other languages
English (en)
Portuguese (pt)
Inventor
Scharschmidt Bruce
Mokhtarani Masoud
Original Assignee
Hyperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49380684&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014026138(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hyperion Therapeutics Inc filed Critical Hyperion Therapeutics Inc
Publication of BR112014026138A2 publication Critical patent/BR112014026138A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
BR112014026138A 2012-04-20 2012-09-11 métodos de monitoramento terapêutico de pró-fármacos de ácido fenilacético BR112014026138A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261636256P 2012-04-20 2012-04-20
PCT/US2012/054673 WO2013158145A1 (en) 2012-04-20 2012-09-11 Methods of therapeutic monitoring of phenylacetic acid prodrugs

Publications (1)

Publication Number Publication Date
BR112014026138A2 true BR112014026138A2 (pt) 2017-06-27

Family

ID=49380684

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014026138A BR112014026138A2 (pt) 2012-04-20 2012-09-11 métodos de monitoramento terapêutico de pró-fármacos de ácido fenilacético

Country Status (25)

Country Link
US (4) US9561197B2 (cg-RX-API-DMAC7.html)
EP (2) EP2846791B1 (cg-RX-API-DMAC7.html)
JP (3) JP6234436B2 (cg-RX-API-DMAC7.html)
KR (2) KR102264579B1 (cg-RX-API-DMAC7.html)
CN (3) CN113995743A (cg-RX-API-DMAC7.html)
AU (3) AU2012377389A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014026138A2 (cg-RX-API-DMAC7.html)
CL (2) CL2014002807A1 (cg-RX-API-DMAC7.html)
CY (1) CY1118838T1 (cg-RX-API-DMAC7.html)
DK (1) DK2846791T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP14024561A (cg-RX-API-DMAC7.html)
ES (2) ES2623470T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20170651T1 (cg-RX-API-DMAC7.html)
HU (1) HUE032726T2 (cg-RX-API-DMAC7.html)
IL (2) IL235127A (cg-RX-API-DMAC7.html)
LT (1) LT2846791T (cg-RX-API-DMAC7.html)
MX (1) MX365302B (cg-RX-API-DMAC7.html)
PL (1) PL2846791T3 (cg-RX-API-DMAC7.html)
PT (1) PT2846791T (cg-RX-API-DMAC7.html)
RS (1) RS55870B1 (cg-RX-API-DMAC7.html)
SG (2) SG10201608749UA (cg-RX-API-DMAC7.html)
SI (1) SI2846791T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201700219T1 (cg-RX-API-DMAC7.html)
WO (1) WO2013158145A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201407597B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3263102A1 (en) 2011-09-30 2018-01-03 Horizon Therapeutics, LLC Methods of therapeutic monitoring of nitrogen scavenging drugs
BR112014026138A2 (pt) 2012-04-20 2017-06-27 Hyperion Therapeutics Inc métodos de monitoramento terapêutico de pró-fármacos de ácido fenilacético
HUE036133T2 (hu) 2012-11-21 2018-06-28 Horizon Therapeutics Llc Eljárások hepatikus enkefalopátia kezelésére szolgáló nitrogénelvonó gyógyszerek beadására és értékelésére
PL2986325T3 (pl) 2013-10-14 2020-03-31 Immedica Pharma Ab Sposoby leczenia zaburzenia cyklu mocznikowego
ES2748294T3 (es) * 2014-06-04 2020-03-16 Immedica Pharma Ab Métodos para tratar trastornos del ciclo de la urea con el fin de prevenir crisis hiperamonémicas controlando los niveles de amoniaco en sangre
US9914692B2 (en) 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
US20190076383A1 (en) * 2017-09-08 2019-03-14 Horizon Therapeutics, Llc Methods for treating urea cycle disorders
US10668040B2 (en) 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
US5635532A (en) 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
US5879657A (en) 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
WO1996024571A1 (en) 1995-02-07 1996-08-15 Brusilow Saul W Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders
US6219567B1 (en) 1999-06-21 2001-04-17 Cardiox Corporation Monitoring of total ammoniacal concentration in blood
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
US20050273359A1 (en) 2004-06-03 2005-12-08 Young David E System and method of evaluating preoperative medical care and determining recommended tests based on patient health history and medical condition and nature of surgical procedure
PT2319581E (pt) 2004-11-26 2015-06-30 Ucl Business Plc Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática
US20060135612A1 (en) 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
US20070004805A1 (en) 2005-07-01 2007-01-04 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
US20100016207A1 (en) 2005-11-10 2010-01-21 Wurtman Richard J Methods and Compositions for Raising Levels and Release of Gamma Aminobutyric Acid
US8094521B2 (en) 2007-02-28 2012-01-10 Nightingale Products LLC Caregiver personal alert device
GB2451259B (en) * 2007-07-25 2011-07-20 Gp Acoustics Loudspeaker
US9078864B2 (en) 2008-01-08 2015-07-14 Akthelia Pharmaceuticals Agonists for antimicrobial peptide systems
GB2465250B (en) * 2008-08-29 2011-01-26 Ucyclyd Pharma Inc Dosing and monitoring patients on nitrogen-scavenging drugs
WO2009134460A1 (en) * 2008-04-29 2009-11-05 Hyperion Therapeutics Methods of treatment using ammonia-scavenging drugs
JP5577341B2 (ja) * 2008-08-29 2014-08-20 ハイペリオン セラピューティクス, インコーポレイテッド アンモニア捕捉薬を使用する処置方法
CN102481269B (zh) * 2009-05-11 2015-10-07 博格有限责任公司 包含辅酶q10的药物组合物及其制备方法
EP2954780A1 (en) 2009-07-24 2015-12-16 Baylor College Of Medicine Methods of modulation of branched chain acids and uses thereof
JP6049619B2 (ja) 2010-08-31 2016-12-21 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ナノヒドロキシアパタイトを含む多孔質多糖足場、及び骨形成のための使用
EP3263102A1 (en) 2011-09-30 2018-01-03 Horizon Therapeutics, LLC Methods of therapeutic monitoring of nitrogen scavenging drugs
BR112014026138A2 (pt) * 2012-04-20 2017-06-27 Hyperion Therapeutics Inc métodos de monitoramento terapêutico de pró-fármacos de ácido fenilacético
HUE036133T2 (hu) 2012-11-21 2018-06-28 Horizon Therapeutics Llc Eljárások hepatikus enkefalopátia kezelésére szolgáló nitrogénelvonó gyógyszerek beadására és értékelésére

Also Published As

Publication number Publication date
ECSP14024561A (es) 2015-09-30
PT2846791T (pt) 2017-05-25
EP2846791B1 (en) 2017-02-08
JP6234436B2 (ja) 2017-11-22
CN104540507A (zh) 2015-04-22
CL2017001375A1 (es) 2018-01-05
PL2846791T3 (pl) 2017-07-31
EP3222275B1 (en) 2020-06-24
AU2019201811B2 (en) 2020-07-09
DK2846791T3 (en) 2017-03-27
EP2846791A4 (en) 2015-08-19
JP6637941B2 (ja) 2020-01-29
JP2015514757A (ja) 2015-05-21
KR20150013170A (ko) 2015-02-04
ES2623470T3 (es) 2017-07-11
HK1243959A1 (en) 2018-07-27
AU2012377389A1 (en) 2014-10-30
EP2846791A1 (en) 2015-03-18
MX2014012694A (es) 2015-06-03
ZA201407597B (en) 2017-05-31
RS55870B1 (sr) 2017-08-31
CL2014002807A1 (es) 2015-02-27
WO2013158145A1 (en) 2013-10-24
AU2018200163B2 (en) 2018-12-20
HK1208380A1 (en) 2016-03-04
US9561197B2 (en) 2017-02-07
US20180263938A1 (en) 2018-09-20
SMT201700219T1 (it) 2017-05-08
SI2846791T1 (sl) 2017-06-30
HRP20170651T1 (hr) 2017-06-30
JP2018039830A (ja) 2018-03-15
US20180015058A1 (en) 2018-01-18
KR102264579B1 (ko) 2021-06-11
AU2019201811A1 (en) 2019-04-04
AU2018200163A1 (en) 2018-02-01
EP3222275A1 (en) 2017-09-27
US20130281530A1 (en) 2013-10-24
HUE032726T2 (en) 2017-10-30
US20170266143A1 (en) 2017-09-21
IL255918A (en) 2018-01-31
CY1118838T1 (el) 2018-01-10
JP2019219413A (ja) 2019-12-26
WO2013158145A9 (en) 2014-05-01
LT2846791T (lt) 2017-04-10
CN111991383A (zh) 2020-11-27
CN113995743A (zh) 2022-02-01
SG10201608749UA (en) 2016-12-29
IL235127A (en) 2017-12-31
KR20190116552A (ko) 2019-10-14
SG11201406745VA (en) 2014-12-30
IL255918B (en) 2019-06-30
ES2807951T3 (es) 2021-02-24
MX365302B (es) 2019-05-29

Similar Documents

Publication Publication Date Title
ECSP14024561A (es) Métodos de monitoreo terapéutico de profármacos de ácido fenilacético
BR112015000329A2 (pt) formulações de diclofenac
CY1120929T1 (el) Λιπιδια για συστασεις διανομης θεραπευτικου παραγοντα
JO3091B1 (ar) مشتقات حمض 3- فنيل بروبيونيك متفرعة واستخداماتها
BR112014019973A2 (pt) sistema de gerenciamento de linha de transmissão
BR112014031310A2 (pt) anticorpos anti-pcsk9, formulações, dosagem e métodos de uso
BR112013010167A2 (pt) sais de dimetilamida do ácido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-ilamino)-7h-pirrol[2,3-d]pirimidino-6-carboxílico e processos para sua produção
BR112015026325A2 (pt) dosagem oral de compostos glp-1
EP2935229A4 (en) Esterification of 2,5-Furan-Dicarboxylic Acid
BR112015005369A2 (pt) inibidores de usp30 e métodos para sua utilização
MX2022011225A (es) Formulaciones farmaceuticas de un inhibidor de hidroxilasa de hif.
BR112013026467A2 (pt) análogos de prostaglandina conjugados com polímero
GT201200293A (es) Marcadores predictivos útiles en el tratamiento del síndrome frágil x (fxs)
BR112012016894A2 (pt) lactobacilos com ação antioxidante.
BR112014005935A2 (pt) derivados de anilina, sua preparação e sua aplicação terapêutica
BR112015025719A2 (pt) terapia contra o câncer
CY1126140T1 (el) Ναλμεφενη για τη μειωση της καταναλωσεως αλκοολης σε συγκεκριμενους πληθυσμους στοχους
BR112015003957A2 (pt) alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria
GT201400242A (es) "nuevos compuestos de pirazol"
BR112014009760A8 (pt) análogos de ácido siálico
BR112014017587A8 (pt) métodos e formulações para o tratamento de deficiências de ácido siálico
CY1118487T1 (el) Αλατα σουλφονικου οξεος υποκατεστημενων με ετεροκυκλυλαμιδιο ιμιδαζολιων
ES2403549R1 (es) Co-cristales de agomelatina con formadores de co-cristales
BR112013031488A2 (pt) composições em gel
BR112015004494A2 (pt) célula de fluxo de permeabilidade e sistema de condutância hidráulica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: HORIZON THERAPEUTICS, INC. (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: HORIZON THERAPEUTICS, LLC (US)

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: IMMEDICA PHARMA AB (SE)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]